InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,861.60
(
-1.17%
)
Dow Jones
38,460.92
(
0.00%
)
Brent Oil
87.50
(
0.32%
)
Bitcoin
63,982.12
(
-0.47%
)
Post# of 251590
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: A deleted message

Friday, 02/17/2017 6:13:18 PM

Friday, February 17, 2017 6:13:18 PM

Post# of 251590
Momenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa(R) (glatiramer acetate injection) Fill/Finish Manufacturer

Approval of the Glatopa 40 mg ANDA will be dependent on resolution of Pfizer facility compliance issues and Momenta expects that an approval in the first quarter of 2017 is unlikely

Warning letter does not restrict the production or shipment of Glatopa 20 mg

http://files.shareholder.com/downloads/MNTA/3909300740x0x928706/9fc3719b-041d-4432-8a9d-0c0e161bcafd/MNTA_News_2017_2_17_General_Releases.pdf
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up